<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01419561</url>
  </required_header>
  <id_info>
    <org_study_id>110220</org_study_id>
    <secondary_id>11-C-0220</secondary_id>
    <nct_id>NCT01419561</nct_id>
  </id_info>
  <brief_title>History of the KSHV Inflammatory Cytokine Syndrome (KICS)</brief_title>
  <official_title>Natural History Study of the KSHV Inflammatory Cytokine Syndrome (KICS) Incorporating Pilot Evaluation of KSHV Targeted Therapies</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Institutes of Health Clinical Center (CC)</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Background:&#xD;
&#xD;
      - KSHV inflammatory cytokine syndrome (KICS) is a newly recognized disease caused by Kaposi&#xD;
      sarcoma-associated herpesvirus (KSHV). This virus can cause cancer. People with KICS can have&#xD;
      severe symptoms. They include fever, weight loss, and fluid in the legs or abdomen. People&#xD;
      with KICS may also be at risk of getting other cancers associated with KSHV. These cancers&#xD;
      include Kaposi sarcoma and lymphoma. Because KICS is a newly identified disease, more&#xD;
      information is needed on how the disease works and what can be done to treat it.&#xD;
&#xD;
      Objectives:&#xD;
&#xD;
      - To collect genetic and medical information from people with KSHV inflammatory cytokine&#xD;
      syndrome.&#xD;
&#xD;
      Eligibility:&#xD;
&#xD;
      - Individuals at least 18 years of age who have Kaposi sarcoma herpes virus and symptoms that&#xD;
      resemble those caused by KICS.&#xD;
&#xD;
      Design:&#xD;
&#xD;
        -  Participants will have regular study visits. The schedule will be determined by the&#xD;
           study researchers.&#xD;
&#xD;
        -  Participants will provide a complete medical history and have a full physical exam.&#xD;
           Blood and urine samples will be collected as well.&#xD;
&#xD;
        -  People with KICS that requires treatment may get new experimental treatments. These&#xD;
           treatments may include antiviral drugs and chemotherapy drugs, depending on the nature&#xD;
           of the disease.&#xD;
&#xD;
        -  Participants will have imaging studies, such as chest x-rays and computed tomography&#xD;
           scans, to study the tumors.&#xD;
&#xD;
        -  Bone marrow and lymph node biopsies may be done to collect tissue samples for study.&#xD;
&#xD;
        -  Participants who have Kaposi sarcoma will have photographs taken of their lesions.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      BACKGROUND:&#xD;
&#xD;
      KSHV inflammatory cytokine syndrome (KICS) is a newly recognized syndrome caused by Kaposi&#xD;
      sarcoma-associated herpesvirus (KSHV). It is characterized by severe inflammatory symptoms&#xD;
      including fevers, wasting, cytopenias, hypoalbuminemia, and hyponatremia, associated in some&#xD;
      cases with lymphadenopathy or effusions, without pathological evidence of MCD. Patients with&#xD;
      KICS exhibit elevated KSHV viral loads and cytokine dysregulation, with elevations of IL-6,&#xD;
      IL-10, and a KSHV-encoded IL-6 homolog, viral IL-6.&#xD;
&#xD;
      OBJECTIVE:&#xD;
&#xD;
      The primary study objective is to enable intensive study and description of the natural&#xD;
      history of KICS.&#xD;
&#xD;
      ELIGIBILITY:&#xD;
&#xD;
      Adults of any HIV status with:&#xD;
&#xD;
        -  At least two symptoms, laboratory or radiographic abnormalities which are at least&#xD;
           possibly attributable to KICS (including fever, fatigue, cachexia, edema, respiratory or&#xD;
           gastrointestinal symptoms, hematologic cytopenias, hypoalbuminemia, hyponatremia,&#xD;
           lymphadenopathy,organomegaly, effusions)&#xD;
&#xD;
        -  C-reactive protein &gt;3mg/L&#xD;
&#xD;
        -  Evidence of KSHV infection or a risk exposure for KSHV infection&#xD;
&#xD;
        -  No evidence of KSHV-associated multicentric Castleman disease&#xD;
&#xD;
      Patients with these characteristics will be further evaluated to identify those whose&#xD;
      clinical and laboratory features are consistent with the working KICS working case definition&#xD;
      to be followed in the natural history phase of the study.&#xD;
&#xD;
      DESIGN:&#xD;
&#xD;
      This is a single center natural history cohort with a cohort of up to 80 patients. Of these,&#xD;
      up to 40 who meet the criteria for KICS will then go onto a natural history arm, with two&#xD;
      nested open label pilot treatment arms. Natural history patients will undergo clinical,&#xD;
      laboratory and correlative assessment every 3 months until sustained resolution and two&#xD;
      nested open label pilot treatment arms. Patients with clinical and laboratory manifestations&#xD;
      of KICS, elevated inflammatory markers and KSHV viral load will be eligible for therapy with&#xD;
      high dose zidovudine/valganciclovir, or if they have intercurrent Kaposi sarcoma (KS)&#xD;
      requiring cytotoxic with rituximab/liposomal doxorubicin on the 2 nested open label pilot&#xD;
      treatment arms. Each treatment arm uses a two-stage design, with interim analysis at 8&#xD;
      patients in each arm and potential accrual of 14 per arm. Patients on the treatment arm who&#xD;
      have not responded to the pilot treatments or for whom such treatment would not be suitable&#xD;
      may also be treated with best available therapy. Participants who require KS and/or primary&#xD;
      effusion lymphoma (PEL) treatment following a KICS diagnosis will receive therapies within&#xD;
      the appropriate arm of the study or be treated for their KS and/or PEL on a separate protocol&#xD;
      while still followed on this study.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 8, 2011</start_date>
  <completion_date type="Anticipated">December 31, 2025</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2025</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Natural history of KICS</measure>
    <time_frame>one year</time_frame>
    <description>Description of the natural history of KICS, including the spectrum of clinical, laboratory and radiographic abnormalities seen in affected patients</description>
  </primary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Anticipated">80</enrollment>
  <condition>KSHV Inflammatory Cytokine Syndrome (KICS)</condition>
  <condition>KSHV</condition>
  <condition>HHV-8</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Evaluation for Alternative Causes of KICS Symptoms</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Natural History/Observation Arm</description>
  </arm_group>
  <arm_group>
    <arm_group_label>3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>High dose zidovudine + valganciclovir</description>
  </arm_group>
  <arm_group>
    <arm_group_label>4</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Rituximab with or without liposomal doxorubicin</description>
  </arm_group>
  <arm_group>
    <arm_group_label>5</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Standard and alternative rational therapies</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Zidovudine</intervention_name>
    <description>Zidovudine 600 mg will be administered orally 4 times a day or i.v. at 300 mg every 6 hours for 14 days for cycle 1 and for 7 days (up to additional 7 days if ongoing symptoms) for following cycles.</description>
    <arm_group_label>3</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Liposomal Doxorubicin</intervention_name>
    <description>Liposomal doxorubicin (20 mg/m2) will be administered i.v. over 1 hour at day 1 of each cycle</description>
    <arm_group_label>4</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Valganiclovir</intervention_name>
    <description>Valganciclovir (900mg) will be administered orally twice/day or Ganciclovir (5 mg/kg) will be administered i.v. over 1 hour for 14 days for cycle 1 and for 7 days (up to additional 7 days if ongoing symptoms) for following cycles.</description>
    <arm_group_label>3</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rituximab</intervention_name>
    <description>Rituximab (375 mg/m2) will be admnistered i.v. at 50 mg/hr up to 100 mg/hr at day 1 of the first cycle and at 100mg/hr up to 400 mg&#xD;
/hr at day 1 of following cycles.</description>
    <arm_group_label>4</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Standard Therapies</intervention_name>
    <description>Standard of Care drugs</description>
    <arm_group_label>5</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        -  INCLUSION CRITERIA:&#xD;
&#xD;
          -  Age greater than or equal to18 Years.&#xD;
&#xD;
          -  Any HIV status.&#xD;
&#xD;
          -  At least two manifestations drawn from at least two of the categories (clinical&#xD;
             symptoms, laboratory abnormalities and radiographic abnormalities), which are at least&#xD;
             possibly attributable to KICS and are not readily explicable from known medical&#xD;
             conditions in the patient:&#xD;
&#xD;
          -  Clinical symptoms (each at least grade 1 by CTCAE definitions)&#xD;
&#xD;
          -  Fever (&gt;38 degrees C), chills or rigors&#xD;
&#xD;
          -  Fatigue or lethargy&#xD;
&#xD;
          -  Cachexia or edema&#xD;
&#xD;
          -  Cough, dyspnea, airway hyperreactivity, or nasal inflammation&#xD;
&#xD;
          -  Nausea, anorexia, abdominal pain or altered bowel habit&#xD;
&#xD;
          -  Athralgia or myalgia&#xD;
&#xD;
          -  Altered mental state&#xD;
&#xD;
          -  Neuropathy with or without pain&#xD;
&#xD;
          -  Laboratory abnormalities&#xD;
&#xD;
          -  Anemia (hemoglobin&lt;12.0g/dL)&#xD;
&#xD;
          -  Thrombocytopenia (platelets&lt;100,000 cells/microL)&#xD;
&#xD;
          -  Leukopenia (white cell count&lt;4,000 cells/microL)&#xD;
&#xD;
          -  Hypoalbuminemia (albumin&lt;3.5g/dL)&#xD;
&#xD;
          -  Hyponatremia (sodium&lt;135mmol/L)&#xD;
&#xD;
          -  Coagulopathy (PT or PTT &gt;1.5 times upper limit of normal)&#xD;
&#xD;
          -  Radiographic Abnormalities&#xD;
&#xD;
          -  Pathologic lymphadenopathy (at least five discrete nodes each &gt;1cm in their longest&#xD;
             dimension)&#xD;
&#xD;
          -  Splenomegaly (&gt;12 cm in the longest dimension)&#xD;
&#xD;
          -  Hepatomegaly (&gt;17cm in the longest dimension)&#xD;
&#xD;
          -  Body cavity effusions not caused by primary effusion lymphoma nor chylous effusions&#xD;
             directly related to lymphatic infiltration by KS&#xD;
&#xD;
             -. C-reactive protein &gt;3mg/L.&#xD;
&#xD;
          -  Exposure risk for KSHV infection (including being a first or second generation&#xD;
             immigrant from an endemic area, or male-to-male sexual activity) or evidence of KSHV&#xD;
             infection demonstrated by one of:&#xD;
&#xD;
               -  Molecular evidence of KSHV in whole blood, confirmed by testing at Focus&#xD;
                  Laboratories, CA (HHV-8 Quantitative PCR, Focus Unit Code 45700) or KSHV viral&#xD;
                  load levels within circulating peripheral blood mononuclear cells (PBMCs) as&#xD;
                  determined by the Whitby laboratory.&#xD;
&#xD;
               -  Immunohistochemical evidence of KSHV in tissues (for example by staining for LANA&#xD;
                  or vIL-6). Confirmed in the Laboratory of Pathology, CCR, NCI.&#xD;
&#xD;
               -  Presence of KS or PEL (KSHV-associated malignancies), confirmed in the Laboratory&#xD;
                  of Pathology, CCR, NCI.&#xD;
&#xD;
          -  Women of child-bearing potential (WOCBP) and men must agree to use adequate&#xD;
             contraception (hormonal or barrier method of birth control; abstinence) prior to study&#xD;
             entry, for the duration of study participation, and for 6 months after the study&#xD;
             treatment. Should a woman become pregnant or suspect she is pregnant while she or her&#xD;
             partner is participating in this study, she should inform her treating physician&#xD;
             immediately.&#xD;
&#xD;
        EXCLUSION CRITERIA:&#xD;
&#xD;
          -  Biopsy proven KSHV-associated MCD, confirmed in the Laboratory of Pathology, CCR, NCI.&#xD;
&#xD;
          -  Pregnancy&#xD;
&#xD;
          -  Any abnormality that would be scored as NCI CTC Grade 4 toxicity that is unrelated to&#xD;
             HIV, its treatment, or to KICS that would preclude the use of all of the study&#xD;
             treatments or the ability to monitor the natural history of KICS untreated.&#xD;
&#xD;
          -  Any condition or set of circumstances that in the opinion of the investigators would&#xD;
             make participation in this study unsafe or otherwise inappropriate for a given&#xD;
             individual.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Robert Yarchoan, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>National Cancer Institute (NCI)</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Anaida Widell</last_name>
    <phone>(240) 760-6074</phone>
    <email>anaida.widell@nih.gov</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Robert Yarchoan, M.D.</last_name>
    <phone>(240) 760-6075</phone>
    <email>robert.yarchoan@nih.gov</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>National Institutes of Health Clinical Center, 9000 Rockville Pike</name>
      <address>
        <city>Bethesda</city>
        <state>Maryland</state>
        <zip>20892</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>For more information at the NIH Clinical Center contact National Cancer Institute Referral Office</last_name>
      <phone>(888) NCI-1937</phone>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://clinicalstudies.info.nih.gov/cgi/detail.cgi?A_2011-C-0220.html</url>
    <description>NIH Clinical Center Detailed Web Page</description>
  </link>
  <reference>
    <citation>Chang Y, Cesarman E, Pessin MS, Lee F, Culpepper J, Knowles DM, Moore PS. Identification of herpesvirus-like DNA sequences in AIDS-associated Kaposi's sarcoma. Science. 1994 Dec 16;266(5192):1865-9.</citation>
    <PMID>7997879</PMID>
  </reference>
  <reference>
    <citation>Moore PS, Gao SJ, Dominguez G, Cesarman E, Lungu O, Knowles DM, Garber R, Pellett PE, McGeoch DJ, Chang Y. Primary characterization of a herpesvirus agent associated with Kaposi's sarcomae. J Virol. 1996 Jan;70(1):549-58. Erratum in: J Virol 1996 Dec;70(12):9083.</citation>
    <PMID>8523568</PMID>
  </reference>
  <reference>
    <citation>Viejo-Borbolla A, Schulz TF. Kaposi's sarcoma-associated herpesvirus (KSHV/HHV8): key aspects of epidemiology and pathogenesis. AIDS Rev. 2003 Oct-Dec;5(4):222-9. Review.</citation>
    <PMID>15012001</PMID>
  </reference>
  <verification_date>September 9, 2021</verification_date>
  <study_first_submitted>August 17, 2011</study_first_submitted>
  <study_first_submitted_qc>August 17, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 18, 2011</study_first_posted>
  <last_update_submitted>October 1, 2021</last_update_submitted>
  <last_update_submitted_qc>October 1, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 4, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>KSHV</keyword>
  <keyword>KICS</keyword>
  <keyword>HIV</keyword>
  <keyword>Cytokines</keyword>
  <keyword>HHV-8</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Syndrome</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Zidovudine</mesh_term>
    <mesh_term>Rituximab</mesh_term>
    <mesh_term>Doxorubicin</mesh_term>
    <mesh_term>Liposomal doxorubicin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

